The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Publications

Demerouti E, Karyofyllis P, Athanassopoulos G, Karatasakis G, Tsiapras D, Manginas A, Voudris V

Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review.

Multiple sclerosis and related disorders. 2019;28:273-275

Papani R, Duarte AG, Lin YL, Kuo YF, Sharma G

Pulmonary arterial hypertension associated with interferon therapy: a population-based study.

Multidisciplinary respiratory medicine. 2017;12:1

Savale L, Chaumais MC, O'Connell C, Humbert M, Sitbon O

Interferon-induced pulmonary hypertension: an update.

Current opinion in pulmonary medicine. 2016;22(5):415-20

Fok A, Williams T, McLean CA, Butler E

Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.

Multiple sclerosis (Houndmills, Basingstoke, England). 2016;22(11):1495-1498

Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S, Jaïs X, Seferian A, Jovan R, Bulifon S, Parent F, Simonneau G, Humbert M, Sitbon O

Pulmonary arterial hypertension in patients treated with interferon.

The European respiratory journal. 2014;44(6):1627-34

Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH

Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.

Digestive diseases and sciences. 2010;55(6):1785-90

Fruehauf S, Steiger S, Topaly J, Ho AD

Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.

Annals of hematology. 2001;80(5):308-10